SCHEMBL27088677

SCHEMBL27088677

COc1ccc(CNc2nccnc2[C@H](C)NCCO)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE2 O96020 7/20 0.51
▸ CCNE1 P24864 7/20 0.51
▸ CDK2 P24941 7/20 0.51
▸ CDK1 P06493 5/20 0.45
▸ CCNB1 P14635 3/20 0.45
▸ CCNB2 O95067 2/20 0.45
▸ CCNB3 Q8WWL7 2/20 0.45
▸ PDE5A O76074 2/20 0.45
▸ CDK5 Q00535 2/20 0.45
▸ PDE4D Q08499 2/20 0.45
▸ CDK5R1 Q15078 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ PRUNE1 Q86TP1 1/20 0.45
▸ CCNT1 O60563 1/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CDK7 P50613 1/20 0.45
▸ CDK9 P50750 1/20 0.45
▸ CCNH P51946 1/20 0.45
▸ MNAT1 P51948 1/20 0.45
▸ PDE10A Q9Y233 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27088683 1.00 CCNE2 (0.51) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL27089334 1.00 CCNE2 (0.51) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL29998917 0.80 CCNE2 (0.45) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL27089192 0.80 CCNE2 (0.45) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL27089188 0.80 CCNE2 (0.45) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL29998666 0.78 CCNE2 (0.46) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL27088974 0.78 CCNE2 (0.46) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL27088969 0.78 CCNE2 (0.46) CCNE2CCNE1CDK2CDK1CCNB1
SCHEMBL29321909 0.78 LMNA (0.41) CCNE2CCNE1CDK2PRUNE1RAB9A
SCHEMBL29333935 0.73 PDCD1LG2 (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383915-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2024-11-21 — — US disclosed
EP-4320132-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-02-14 — — EP disclosed
CN-117083279-A Oxazepine compounds and their use in the treatment of cancer 基因泰克公司 2023-11-17 — — CN disclosed
WO-2022216762-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2022-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383915-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER OXA1L, GRIK4, GRIK5 CCNE2 3042/4885CCNE1 2384/4885CDK2 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback